Bio-International 2

Bioavailability, Bioequivalence and Pharmacokinetic Studies

International Conference of F.I.P. “Bio-International ‘94” held in Munich, Germany, June 15–17, 1994

Pre Satellite Symposium:
In Vivo/In Vitro Correlation:
How to Assess Dissolution Specifications for Quality Control
14 June 1994

Post Satellite Symposium:
Update on Analytical Method Validation
18 June 1994

Edited by

Henning H. Blume
President of Section for Official Laboratories and Medicines Control Services of F.I.P.
Associated Professor of Pharmacy, University of Frankfurt, Germany
Director of Zentrallaboratorium Deutscher Apotheker,
Eschborn/Frankfurt, Germany

Kamal K. Midha
Chairman of the Board of Pharmaceutical Sciences of F.I.P.
Professor of Pharmacy and Associate Member of Department of Psychiatry,
Colleges of Pharmacy and Medicine, University of Saskatchewan, Saskatoon, Canada

With 144 figures and 65 tables

Scientific Publishers Stuttgart 1995
Contents

Contributors .................................................. 11
Preface ......................................................... 13
Note on Organization ........................................ 14

Main Conference:
Bioavailability, Bioequivalence and Pharmacokinetic Studies 15

I. Bioequivalence: Quality Control and Therapeutic Surrogate? ........................................ 27
Aims and Consequences of Bioequivalence Studies ......................................................... 29
Kamal K. Midha and John W. Hubbard
Bioequivalence – A Measure of Therapeutic Equivalence? ........................................... 35
Geoffrey T. Tucker, Armin Rostami-Hodjegan and Peter R. Jackson
Bioequivalence – A Measure of Quality Control? ......................................................... 45
Peter G. Welling
Metrics of Absorption: Simulation Approach .............................................................. 51
Thomas N. Tozer and Frédéric Y. Bois
Metrics of Absorption: Data Base Analysis ................................................................. 61
Martina Elze, Henrike Potthast and Henning H. Blume
Evaluation of Different Metrics as Indirect Measures of Rate of Drug Absorption ......... 73
Lawrence F. Lacey, Oliver N. Keene and Alan Bye
Metrics Assessing Absorption Rates: Principles, and Determination of Bioequivalence in the Steady State ................................................................. 77
Laszlo Endrenyi, Laszlo Tothfalusi and Jiuhong Zha
Individual vs. Average Bioequivalence: When is Average not Sufficient? ................. 87
Walter W. Hauck and Sharon Anderson
A Unified View of Individual, Population, and Average Bioequivalence ..................... 91
Robert Schall

II. Bioequivalence of Highly Variable Drugs ................................................................. 107
An Overview of Problems and Progress at Bio-Internationals ’89 and ’92 .................. 109
Iain J. McGilveray
Practical Strategies and Design Advantages in Highly Variable Drug Studies: Multiple Dose and Replicate Administration Design ........................................ 117
Henning H. Blume, Martina Elze, Henrike Potthast and Barbara S. Schug
Practical Strategies and Design Advantages for Highly Variable Drugs: Replicate Design .......................... 123
Kamal K. Midha, Maureen Rawson and John W. Hubbard; Eric D. Ormsby

Are We Expecting too much from Replicate Designs? ............................................. 129
Eric D. Ormsby

Possible Decision Rules for Bioequivalence of Highly Variable Drugs:
Issues and Perspectives ......................................................... 135
Luc P. Balant and Marianne Gex-Fabry

Regulatory Concerns About Highly Variable Drugs,
Bioequivalence/Interchangeability ............................................. 147
Roger L. Williams

III. Bioavailability/Bioequivalence in Market Application
of New Active Substances ...................................................... 149

Current Requirements in Bioavailability Dossiers for New Active Substances 151
Leslie Z. Benet

Pre-Clinical/Toxicokinetic Implications of Bioavailability Studies 153
Dennis A. Smith

Special Bioavailability Problems with Biotechnology-Derived Drugs 159
Ronald T. Borchardt

Problems of Assessment of Bioavailability/Bioequivalence
of Administered Endogenous Substances .................................. 161
Stephen Toon

Regulatory Requirements for Bioavailability Studies of New Active Substances I 171
José A. G. Morais

Regulatory Requirements for Bioavailability Studies of New Active Substances II 181
Thomas M. Ludden

IV. Bioavailability/Bioequivalence of Modified Release Products ............................ 183

Pharmacokinetic and Clinical/Pharmacodynamic Considerations in Developing
Modified Release Dosage Forms with Focus on Functional Tolerance Development 185
Lennart K. Paalzow

Shape Analysis in Single- and Multiple-Dose Studies of Modified Release Products 193
Volker W. Steinijans, Rita Sauter and Edgar Diletti

Patient Compliance Considerations in Use of Modified Release
over Immediate Release Dosage Forms ................................... 207
Ursula Gundert-Remy

Bioavailability and Bioequivalence of Modified Release Dosage Forms:
General Concepts ................................................................. 211
Lawrence J. Lesko

CPMP Guidance on Modified Release Products and Beyond .............................. 219
Adalbert G. Rauws
Bioequivalence Test for Oral Controlled Release Dosage Forms in Japan 225
Nobuo Aoyagi

Bioavailability/Bioequivalence: Need to Know versus Nice to Know versus Want to Know – The Regulatory Perspective 233
Maria Holz-Slomczyk and Alfred Hildebrand

Pre Conference Report:
In Vivo/In Vitro Correlation: How to assess Dissolution Specifications for Quality Control 239

I. In Vitro Characterization of Oral Dosage Forms; Correlation Techniques 245
Development of Dissolution Tests for Immediate Release and Modified Release Oral Dosage Forms 247
Shrikant V. Dighe

Calibration of Dissolution Apparatus 257
L. Timothy Grady

In Vitro Validation of Dissolution Tests 259
Jan-Olof Waltersson

Critical Manufacturing Variables and In Vitro Dissolution Tests in View of In Vivo Performance 261
Andreas Ohm

In Vitro/In Vivo Correlations and Statistics 281
David J. Cutler

II. In Vivo Validation of In Vitro Dissolution Tests and Specifications 291
In Vivo Validation of In Vitro Dissolution Tests and Specifications: Application for Controlled/Modified Release Products 293
Martin Siewert

Expected Variation in Bioavailability for Water Insoluble Drugs 301
John R. Crison and Gordon L. Amidon

In Vivo/In Vitro Correlation: How to Assess Dissolution Specifications for Quality Control – Cases of Non-Correlation, Alternative Approaches 311
Henry J. Malinowski

Key Aspects for a General Concept 317
Roger L. Williams

Post Conference:
Update on Analytical Method Validation 319

I. Problem Resolution and Bioanalytical Method Validation 319
Analytical Methods Validation, Onwards from Arlington 1990 321
Vinod P. Shah and Kamal K. Midha
Contents

Management of the Quality of the Estimate – Concentration to Dosage Form Assessment ................................................. 325
William T. Robinson

Experience with Chromatographic Methods – Europe ...................................... 331
Christa Hartmann, Wim Penninckx, Yvan Vander Heyden, Pieter Vankeerberghen and Desiré L. Massart
Robert D. McDowall

Bioanalytical Validation – A North American View ........................................... 347
John W. Hooper

Experiences with the Development and Validation of Analytical Methods Using HPLC Coupled to Mass Spectrometry ...................... 357
Richard W. Edom

Experience with Mass Spectrometry Procedures – Europe ................................... 359
Elwin R. Verheij and Jan van der Greef

Validation in Practice – Experience with Immunoassay ..................................... 361
John W. A. Findlay

Consequences of Variation of Bioanalytical Methods on Estimation of Pharmacokinetic Parameters – Simulation and Laboratory Experience ............................................. 371
Jaap Wieling, Berend Oosterhuis and Jan H. G. Jonkman

Estimation of Limit of Quantitation ............................................................... 387
Thomas M. Ludden

II. Discussion of Some Remaining Issues ................................................................... 389

Sensitive Enantioselective Determination of an Amino Acid Type Chiral Drug, L-Thyroxine, in HPLC After Derivatization with NBD-F ................................................................. 391
Kazuhiro Imai and Takeshi Fukushima

Analytical Method Validation of Chiral Assays .................................................. 395
Hiltrud Fieger

Replicate Analysis – Not Again ............................................................................. 397
Keith Gallicano, Eric D. Ormsby and Iain J. McGilveray

Standard Curve ................................................................................................. 399
Anthony J. Pateman

Limits of Variability .......................................................................................... 405
Avraham Yacobi and Alfred P. Tonelli